Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Multiple Sclerosis, Relapsing-Remitting FOR PRE-TREATMENT To be eligible for entry into the study, patients must meet the following at the time of enrollment. Re-assessment of the will occur on day zero of the twelve-month treatment phase. Between the ages of 18 and 65 years, inclusive. Patients with relapsing-remitting MS according to published criteria. EDSS score between 1.0 and 5.5. Patients have either failed standard therapies (interferon-beta, glatiramer acetate) by clinical measures, or are not eligible for standard therapies, or opted not to start or continue with any of the standard therapies. Patients are able to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not considered part of routine patient care. Age for in this study follow those of published diagnostic for multiple sclerosis. Due to the uncommon occurrence of MS in individuals under the age of 18 and the requirement to study a large MS cohort to these rarely occurring patients, this is an appropriate lower age range. Patient decision not to start, or not to continue with standard immunomodulatory therapy, has to be made by the patient after discussing conventional treatment options to ensure the patient has made an informed decision. Additionally, the consent document provided to the patient will explicitly state the currently approved therapies and their potential benefits. FOR To be eligible to proceed to the treatment phase of the study, patients must have at least two new gadolinium-enhancing lesions or greater in the four sequential baseline MRI scans (average of greater than or equal to 0.5 gadolinium-enhancing lesions or more). Patients can not have a relapse during 30 days before initiation of treatment. If a relapse occurs during this period and are otherwise fulfilled, treatment (day one) will be delayed while corticosteroids are administered. If corticosteroids are administered, the MRI during that period will not be considered. An additional MRI will be added at 4 weeks following the completion of corticosteroids, to maintain a total of four MRI's that are analyzed in the baseline period. In the event of relapse, the baseline period will be prolonged, as necessary, to meet these criteria  FOR PRE-TREATMENT Patients will be excluded from the study if any of the exist at the time of enrollment. Re-assessment of the will occur on day zero of the twelve month treatment phase. Diagnosis of secondary-progressive or primary-progressive MS, as defined by published diagnostic criteria. Abnormal screening/baseline blood tests exceeding any of the limits defined below Serum alanine transaminase or aspartate transaminase levels which are greater than three times the upper limit of normal values Total white blood cell count less than 3000/mm(3) Platelet count less than 85000/mm(3) Serum creatinine level greater than 2.0 mg/dl Serological evidence of HIV or active hepatitis A, B or C infection since the effects of daclizumab are not defined in these patients Positive pregnancy test Pregnant or breast-feeding female. History or signs of immunodeficiency. Concurrent clinically significant (as determined by the investigators) cardiac, immunological, pulmonary, neurological, renal or other major disease. Any contraindication to monoclonal antibody therapy. Contraindication to monoclonal antibody therapy includes prior history of serum-sickness or similar hypersensitivity reaction to receipt of monoclonal antibody or intravenous immunoglobulin therapies. Patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not considered part of routine patient care. If prior treatments were administered, the patient must be off the following treatment agents for the required period prior to enrollment Glatiramer acetate, interferon-beta